Compare BlackRock TCP Capital Corp (TCPC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs GeneDx Holdings Corp — how do they compare? BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 6× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold BlackRock TCP Capital Corp for 88 Days and GeneDx Holdings Corp for 19 Days on average.
| TCPC | WGS | |
|---|---|---|
Market Cap | $337.71M | $2.02B |
Volume | 436,109 | 734,640 |
Sector | Financials | Health |
52-Week High | $6.20 | $167.51 |
52-Week Low | $3.13 | $34.51 |
Typical Hold Time | 88 Days | 19 Days |
Enterprise Value | $1.09B | $2.05B |
Dividend Yield | 18.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $4.035, up 2.41% today, with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 beating estimates but faces negative revenue and net income trends. Recent portfolio sales and strategic reviews aim to reduce leverage and enhance shareholder value. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
Outlook remains cautious due to declining revenue and negative profitability metrics, though strategic moves may stabilize operations. Key risks include ongoing financial losses and competitive pressures in the BDC sector. Investment opportunity hinges on successful execution of portfolio optimization and debt reduction initiatives.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
